An experimental cancer drug, known as CADD522, may offer a novel approach to addressing osteoporosis and midlife weight gain in women, according to a recent study. Developed to inhibit a protein crucial for cancer growth and spread, the drug has shown potential in strengthening bones and promoting leanness in post-menopausal mice.
Osteoporosis affects a significant portion of women over 50, increasing vulnerability to fractures. Current treatments often come with side effects, safety concerns, or complex dosing schedules, making long-term adherence challenging. Researchers at the University of East Anglia explored CADD522 as a potential alternative, aiming to tackle bone loss while also addressing metabolic changes associated with menopause.
The research, published in the journal npj Drug Discovery, involved mice that underwent surgical procedures to mimic menopausal hormonal shifts. Over an eight-week period, mice treated with CADD522 demonstrated notable improvements in bone health. Scans revealed increased bone volume and better preservation of the internal bone structure, which is vital for strength. Blood tests indicated that the drug stimulated new bone growth without disrupting the natural bone remodeling process.
Beyond bone health, the study observed that mice receiving CADD522 maintained lower body weight compared to their untreated counterparts, despite consuming the same amount of food. These mice also exhibited reduced body fat and less fat accumulation in bone marrow, a phenomenon often linked to declining bone health after menopause.
Further analysis of brain tissue suggested that CADD522 might reverse certain menopause-related changes in fatty acids. Levels of beneficial omega-3 fats remained stable, and other lipid abnormalities shifted toward healthier patterns. While memory and cognitive function were not directly tested, these findings raise possibilities about the drug's potential to address broader health issues related to menopause.
Safety evaluations in mice, rats, and dogs indicated that CADD522 is well-tolerated and can be administered orally. The drug also appeared to be metabolized more slowly in human tissue than in rodents, suggesting potentially enhanced efficacy in people. Researchers noted that these findings are preliminary, as the drug has only been tested in animals, but expressed hope that these benefits will translate to humans, ultimately reducing fracture rates.